CN100431607C - 一种抗实体肿瘤的药物组合物 - Google Patents
一种抗实体肿瘤的药物组合物 Download PDFInfo
- Publication number
- CN100431607C CN100431607C CNB2005100424368A CN200510042436A CN100431607C CN 100431607 C CN100431607 C CN 100431607C CN B2005100424368 A CNB2005100424368 A CN B2005100424368A CN 200510042436 A CN200510042436 A CN 200510042436A CN 100431607 C CN100431607 C CN 100431607C
- Authority
- CN
- China
- Prior art keywords
- guanine
- benzyl
- tumor
- entity
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 94
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims abstract description 160
- 239000003814 drug Substances 0.000 claims abstract description 64
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 230000001093 anti-cancer Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 229960005524 O6-benzylguanine Drugs 0.000 claims description 45
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 25
- KRWMERLEINMZFT-UHFFFAOYSA-N O6-benzylguanine Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 claims description 24
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 22
- 229920001577 copolymer Polymers 0.000 claims description 19
- 229960001756 oxaliplatin Drugs 0.000 claims description 18
- 239000004626 polylactic acid Substances 0.000 claims description 16
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 13
- 229960004316 cisplatin Drugs 0.000 claims description 13
- OFJWFSNDPCAWDK-UHFFFAOYSA-N 2-phenylbutyric acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1 OFJWFSNDPCAWDK-UHFFFAOYSA-N 0.000 claims description 12
- 229960004562 carboplatin Drugs 0.000 claims description 12
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 12
- QILMIEMHJSZECS-UHFFFAOYSA-N [Pt].CCCCCCC Chemical compound [Pt].CCCCCCC QILMIEMHJSZECS-UHFFFAOYSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 claims description 10
- 229950001640 dexormaplatin Drugs 0.000 claims description 10
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 10
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 claims description 9
- SPHOZXNZJHRHSL-UHFFFAOYSA-N 6-butoxy-7h-purin-2-amine Chemical compound CCCCOC1=NC(N)=NC2=C1NC=N2 SPHOZXNZJHRHSL-UHFFFAOYSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 8
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 8
- XWNJMSJGJFSGRY-UHFFFAOYSA-N 2-(benzylamino)-3,7-dihydropurin-6-one Chemical compound N1C=2N=CNC=2C(=O)N=C1NCC1=CC=CC=C1 XWNJMSJGJFSGRY-UHFFFAOYSA-N 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 210000001685 thyroid gland Anatomy 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 3
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000005075 mammary gland Anatomy 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 210000001989 nasopharynx Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 229920000305 Nylon 6,10 Polymers 0.000 claims 4
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 13
- 238000000034 method Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 238000001959 radiotherapy Methods 0.000 abstract description 3
- 231100000057 systemic toxicity Toxicity 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 150000003058 platinum compounds Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 18
- 239000001301 oxygen Substances 0.000 description 16
- 229910052760 oxygen Inorganic materials 0.000 description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 15
- -1 DNA-2114 Chemical compound 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 11
- NAFFDQVVNWTDJD-UHFFFAOYSA-L [4-(azanidylmethyl)oxan-4-yl]methylazanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC1(C[NH-])CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 NAFFDQVVNWTDJD-UHFFFAOYSA-L 0.000 description 10
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 10
- 229950010625 enloplatin Drugs 0.000 description 10
- 229910052697 platinum Inorganic materials 0.000 description 9
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229920002732 Polyanhydride Polymers 0.000 description 8
- KMLCRELJHYKIIL-UHFFFAOYSA-N [1-(azanidylmethyl)cyclohexyl]methylazanide;platinum(2+);sulfuric acid Chemical compound [Pt+2].OS(O)(=O)=O.[NH-]CC1(C[NH-])CCCCC1 KMLCRELJHYKIIL-UHFFFAOYSA-N 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 229940029575 guanosine Drugs 0.000 description 8
- 229950004330 spiroplatin Drugs 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- LQGKRWOLAMMNQG-UTYJZAQGSA-L cyclobutane-1,1-dicarboxylate;(2r)-2-methylbutane-1,4-diamine;platinum(2+) Chemical compound [Pt+2].NC[C@H](C)CCN.[O-]C(=O)C1(C([O-])=O)CCC1 LQGKRWOLAMMNQG-UTYJZAQGSA-L 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 229950008991 lobaplatin Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 229950000959 sebriplatin Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- OOMDVERDMZLRFX-UHFFFAOYSA-N 2,2-bis(aminomethyl)propane-1,3-diol;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound [Pt].NCC(CN)(CO)CO.OC(=O)C1(C(O)=O)CCC1 OOMDVERDMZLRFX-UHFFFAOYSA-N 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241000209094 Oryza Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- 229920000954 Polyglycolide Polymers 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 5
- 201000008275 breast carcinoma Diseases 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 229950007221 nedaplatin Drugs 0.000 description 5
- 239000004633 polyglycolic acid Substances 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229950003017 zeniplatin Drugs 0.000 description 5
- HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 description 4
- VPMJBCMAJPZWIC-UHFFFAOYSA-N 2-amino-6-phenylmethoxy-7,9-dihydropurin-8-one Chemical compound C=12NC(O)=NC2=NC(N)=NC=1OCC1=CC=CC=C1 VPMJBCMAJPZWIC-UHFFFAOYSA-N 0.000 description 4
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 229920005576 aliphatic polyanhydride Polymers 0.000 description 4
- 238000005893 bromination reaction Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229950010897 iproplatin Drugs 0.000 description 4
- 229950008017 ormaplatin Drugs 0.000 description 4
- 229920002627 poly(phosphazenes) Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- MTEDBOAIQUHDQD-YNEHKIRRSA-N (2r,3s,5r)-5-(2-amino-6-phenylmethoxypurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C=12N=CN([C@@H]3O[C@H](CO)[C@@H](O)C3)C2=NC(N)=NC=1OCC1=CC=CC=C1 MTEDBOAIQUHDQD-YNEHKIRRSA-N 0.000 description 3
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- 229920001273 Polyhydroxy acid Polymers 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Natural products O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- UIESMAIMBNSQQX-UHFFFAOYSA-N cyclohexane platinum Chemical compound [Pt].C1CCCCC1 UIESMAIMBNSQQX-UHFFFAOYSA-N 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 229950004403 polifeprosan Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 2
- XSQWTUFYGIMUNS-UHFFFAOYSA-N 6-chloro-8-methyl-7h-purin-2-amine Chemical compound NC1=NC(Cl)=C2NC(C)=NC2=N1 XSQWTUFYGIMUNS-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000011254 conventional chemotherapy Methods 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- LWYXQHQQWVZSOQ-XNIJJKJLSA-N (2r,3r,4s,5r)-2-(2-amino-6-phenylmethoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=NC(N)=NC=1OCC1=CC=CC=C1 LWYXQHQQWVZSOQ-XNIJJKJLSA-N 0.000 description 1
- YFELASZOLXPPCZ-UHFFFAOYSA-N 1-(cyclopenten-1-yl)-2-(methylamino)-7H-purin-6-one Chemical compound C1(=CCCC1)N1C(NC)=NC=2N=CNC2C1=O YFELASZOLXPPCZ-UHFFFAOYSA-N 0.000 description 1
- PWTWXXBATHAPFZ-UHFFFAOYSA-N 2-amino-1-(cyclobuten-1-ylmethyl)-7H-purin-6-one Chemical compound C1(=CCC1)CN1C(N)=NC=2N=CNC2C1=O PWTWXXBATHAPFZ-UHFFFAOYSA-N 0.000 description 1
- JUJPKFNFCWJBCX-UHFFFAOYSA-N 6-[(4-bromothiophen-2-yl)methoxy]-7h-purin-2-amine Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC(Br)=CS1 JUJPKFNFCWJBCX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- KLSFMHCZUOUIFN-AHQWSQKMSA-N C(C1=CC=CC=C1)OC=1C=2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2N=C(N1)N.C(C1=CC=CC=C1)OC=1C=2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2N=C(N1)N Chemical compound C(C1=CC=CC=C1)OC=1C=2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2N=C(N1)N.C(C1=CC=CC=C1)OC=1C=2N=CN([C@H]3C[C@H](O)[C@@H](CO)O3)C2N=C(N1)N KLSFMHCZUOUIFN-AHQWSQKMSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 238000000685 Carr-Purcell-Meiboom-Gill pulse sequence Methods 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 190000032366 Miboplatin Chemical compound 0.000 description 1
- LPRFWTMFAFSZLK-UHFFFAOYSA-N NC1=NC(=C2NC(=NC2=N1)C)Cl.NC1=NC(=C2NC(=NC2=N1)C)Cl Chemical compound NC1=NC(=C2NC(=NC2=N1)C)Cl.NC1=NC(=C2NC(=NC2=N1)C)Cl LPRFWTMFAFSZLK-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- HBPQPBSTHOHSFP-UHFFFAOYSA-N OC(=O)C([Pt])=O Chemical compound OC(=O)C([Pt])=O HBPQPBSTHOHSFP-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 238000002653 magnetic therapy Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- 229950002777 miboplatin Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- LAIWOVGMPGLWTI-SCFUHWHPSA-N n-[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-phenylmethoxypurin-2-yl]acetamide Chemical compound C=12N=CN([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=NC(NC(=O)C)=NC=1OCC1=CC=CC=C1 LAIWOVGMPGLWTI-SCFUHWHPSA-N 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229920001558 organosilicon polymer Polymers 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
瘤细胞 | 庚铂 | 得那铂 | 洛铂 | 司铂 | 右奥马铂 | 恩洛铂 | 米铂 | 奈达铂 | 奥沙利铂 |
CNS | 68% | 64% | 66% | 64% | 90% | 56% | 58% | 49% | 56% |
C6 | 62% | 64% | 60% | 64% | 96% | 60% | 68% | 64% | 54% |
SA | 58% | 60% | 56% | 60% | 86% | 56% | 62% | 62% | 62% |
BC | 54% | 64% | 54% | 54% | 94% | 64% | 64% | 60% | 62% |
BA | 54% | 62% | 62% | 52% | 98% | 62% | 62% | 58% | 60% |
LH | 60% | 58% | 62% | 68% | 90% | 62% | 58% | 56% | 64% |
PAT | 54% | 56% | 66% | 66% | 94% | 56% | 58% | 59% | 58% |
试验组(n) | 所受治疗 | 肿瘤体积(cm<sup>3</sup>) | P值 |
1(6) | 对照 | 82.5±12cm<sup>3</sup> | |
2(6) | 右奥马铂 | 64±10cm<sup>3</sup> | <0.05 |
3(6) | 奥沙利铂 | 61±8cm<sup>3</sup> | <0.01 |
4(6) | 洛铂 | 54±6cm<sup>3</sup> | <0.01 |
5(6) | 庚铂 | 58±6.4cm<sup>3</sup> | <0.01 |
6(6) | 恩洛铂 | 56±6.8cm<sup>3</sup> | <0.01 |
7(6) | 米铂 | 38±4.6cm<sup>3</sup> | <0.001 |
8(6) | 螺铂 | 36±3.6cm<sup>3</sup> | <0.001 |
9(6) | 折尼铂 | 34±4.6cm<sup>3</sup> | <0.001 |
10(6) | 司铂 | 28±2.6cm<sup>3</sup> | <0.001 |
试验组(n) | 所受治疗 | 肿瘤体积(cm<sup>3</sup>) | P值 |
1(6) | 对照 | 88±16 | |
2(6) | 奥沙利铂(ip) | 58±10.3 | <0.05 |
3(6) | 奥沙利铂(it) | 48±12.3 | <0.01 |
4(6) | 奥沙利铂(itp) | 36±9.4 | <0.01 |
5(6) | 庚铂(ip) | 48±6.0 | <0.01 |
6(6) | 庚铂(it) | 44±5.0 | <0.01 |
7(6) | 庚铂(itp) | 33±3.0 | <0.001 |
8(6) | 恩洛铂(ip) | 42±6.6 | <0.001 |
9(6) | 恩洛铂(it) | 22±3.6 | <0.001 |
10(6) | 恩洛铂(itp) | 18±3.6 | <0.001 |
试验组(n) | 所受治疗 | 肿瘤体积(cm<sup>3</sup>) | P值 |
1(6) | 对照 | 84±12 | |
2(6) | 奥沙利铂 | 48±8.3 | <0.05 |
3(6) | 庚铂 | 58±10.3 | <0.01 |
4(6) | 顺铂 | 56±11.4 | <0.01 |
5(6) | 卡铂 | 58±12.0 | <0.01 |
6(6) | O6-BG | 64±13.0 | <0.01 |
7(6) | 奥沙利铂+O6-BG | 30±8.0 | <0.001 |
8(6) | 庚铂+O6-BG | 22±3.6 | <0.001 |
9(6) | 顺铂+O6-BG | 20±3.6 | <0.001 |
10(6) | 卡铂+O6-BG | 18±3.6 | <0.001 |
甲基转移酶抑制剂 | 甲基转移酶抑制率(%) |
O6-苄基鸟嘌呤2-氨基-6-羟嘌呤苄基鸟嘌呤O6-丁基鸟嘌呤O6-甲基鸟嘌呤O6-烷基鸟嘌呤2-氨基-6-氧嘌呤O6-苄基2’-脱氧鸟苷8-氨基-O6-苄基鸟嘌呤8-甲基-O6-苄基鸟嘌呤8-羟基-O6-苄基鸟嘌呤8-溴基-O6-苄基鸟嘌呤8-氧-O6-苄基鸟嘌呤8-三氟甲基-O6-苄基鸟嘌呤O6-苄基尿酸O6-苄基黄嘌呤O6-苄基-2-氟次黄嘌呤二乙酰-O6-苄基-8-氧鸟嘌呤O6-苄基-8-甲基鸟嘌呤O6-苄基-8-氧代鸟嘌呤O6-苄基-8-溴化鸟嘌呤O6-苄基-8-三氟甲基鸟嘌呤O6-苄基-N2-甲基鸟嘌呤O6-苄基-N2N2-二甲基鸟嘌呤O6-苄基-8-三氟甲基-9-甲基鸟嘌呤O6-苄基-8-溴基-9-甲基鸟嘌呤O6-苄基-8-溴基-9-新戊酰氧甲鸟嘌呤O6-苄基-7-新戊酰氧甲基鸟嘌呤O6-苄基-8-溴基-7-新戊酰氧甲鸟嘌呤8-氮杂-O6-苄基-7-新戊酰氧甲鸟嘌呤8-氮杂-O6-苄基-7-新戊酰氧甲鸟嘌呤8-氮杂-O6-苄基鸟嘌呤8-氮杂-O6-苄基-9-甲基鸟嘌呤乙酰基-O6-苄基-8-氧基鸟嘌呤O6-苄基-N2-甲基鸟嘌呤O6-苄基-N2N2-二甲基鸟嘌呤2-氨基-6-氯-8-甲基嘌呤 | 88606680808480808878787890864846484886888890686870808682808486908082826068 |
2,8-二氨基-6-氯嘌呤O6-苄基-N2-鸟苷O6-苄基-9-氰基鸟嘌呤O6-苄基-N2-鸟苷N(7)-甲基鸟嘌呤O6-环链烯基鸟嘌呤1-环丁烯甲基鸟嘌呤1-环戊烯基甲基鸟嘌呤O6-溴噻吡二胺基鸟嘌呤 | 627880808688868689 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100424368A CN100431607C (zh) | 2005-02-03 | 2005-02-03 | 一种抗实体肿瘤的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100424368A CN100431607C (zh) | 2005-02-03 | 2005-02-03 | 一种抗实体肿瘤的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1679951A CN1679951A (zh) | 2005-10-12 |
CN100431607C true CN100431607C (zh) | 2008-11-12 |
Family
ID=35066944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100424368A Expired - Fee Related CN100431607C (zh) | 2005-02-03 | 2005-02-03 | 一种抗实体肿瘤的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100431607C (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1341418A (zh) * | 2001-09-14 | 2002-03-27 | 殷劲 | 增效型抗癌药物 |
WO2003080077A1 (fr) * | 2002-03-26 | 2003-10-02 | Banyu Pharmaceutical Co., Ltd. | Utilisation combinee de derives anticancereux de l'indolopyrrolocarbazole et d'un autre agent anticancereux |
-
2005
- 2005-02-03 CN CNB2005100424368A patent/CN100431607C/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1341418A (zh) * | 2001-09-14 | 2002-03-27 | 殷劲 | 增效型抗癌药物 |
WO2003080077A1 (fr) * | 2002-03-26 | 2003-10-02 | Banyu Pharmaceutical Co., Ltd. | Utilisation combinee de derives anticancereux de l'indolopyrrolocarbazole et d'un autre agent anticancereux |
Non-Patent Citations (4)
Title |
---|
O6-苄基鸟嘌呤逆转人脑胶质瘤对BCNU耐药性的研究. 官卫.中华神经外科杂志,第18卷第2期. 2002 |
O6-苄基鸟嘌呤逆转人脑胶质瘤对BCNU耐药性的研究. 官卫.中华神经外科杂志,第18卷第2期. 2002 * |
顺铂对A549细胞DNA修复酶MGMT和DNA-PKCS表达的影响. 张霞.环境与职业医学,第21卷第1期. 2004 |
顺铂对A549细胞DNA修复酶MGMT和DNA-PKCS表达的影响. 张霞.环境与职业医学,第21卷第1期. 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1679951A (zh) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101336899A (zh) | 含紫杉烷的抗癌缓释注射剂 | |
CN100500219C (zh) | 一种含铂类化合物的抗实体肿瘤药物组合物 | |
CN1923171B (zh) | 同载抗癌抗生素及其增效剂的复方抗癌药物缓释剂 | |
CN100431607C (zh) | 一种抗实体肿瘤的药物组合物 | |
CN100563711C (zh) | 一种抗癌缓释注射剂 | |
CN1311818C (zh) | 一种抗实体肿瘤的药物组合物 | |
CN100569288C (zh) | 一种抗实体肿瘤药物组合物 | |
CN100431605C (zh) | 一种抗癌药物组合物 | |
CN1299774C (zh) | 一种植入体内缓慢释放的抗癌药物组合物 | |
CN100464783C (zh) | 一种含抗肿瘤抗生素的抗癌药物组合物 | |
CN1311872C (zh) | 一种抗癌药物组合物 | |
CN100402091C (zh) | 一种抗癌药物组合物 | |
CN100500220C (zh) | 一种含血管抑制剂的抗实体肿瘤药物组合物 | |
CN1330299C (zh) | 一种治疗颅外实体肿瘤的药物组合物 | |
CN101249066A (zh) | 一种含激素类抗癌药物缓释剂 | |
CN100340296C (zh) | 一种抗癌体内植入剂 | |
CN100464785C (zh) | 一种抗癌药物缓释注射剂及其应用 | |
CN100386115C (zh) | 一种抗癌药物组合物 | |
CN1875959B (zh) | 一种抗癌药物组合物 | |
CN100500217C (zh) | 一种抗实体肿瘤药物组合物 | |
CN100369632C (zh) | 抗癌药物组合物 | |
CN100563710C (zh) | 含嘧啶类似物的抗癌药物缓释剂 | |
CN100586478C (zh) | 一种抗实体肿瘤药物组合物 | |
CN1676165A (zh) | 一种体内缓慢释放的抗癌药物组合物 | |
CN101336898A (zh) | 同载铂类药物及其增效剂的抗癌缓释剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Co-patentee after: Kong Qingzhong Patentee after: Shandong Lanjin Pharmaceuticals Co., Ltd. Address before: 250100 No. 69, building 7, Pioneer Park, Huayang Road, Ji'nan hi tech Development Zone, Shandong, -802 Co-patentee before: Kong Qingzhong Patentee before: Shandong Lanjin Pharmaceuticals Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHANDONG ENDUO BIOLOGICAL PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANDONG LANJIN BIOENGINEERING CO., LTD. Effective date: 20110315 Free format text: FORMER OWNER: KONG QINGZHONG |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 NO. 1750, TIANCHEN ROAD, HIGH-TECH. ZONE, JI'NAN CITY, SHANDONG PROVINCE TO: 250101 ROOM 201, NO. 1750, TIANCHEN ROAD, HIGH-TECH. ZONE, JI'NAN CITY, SHANDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110315 Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Room 201 Patentee after: Shandong many biological pharmaceutical Co., Ltd. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Co-patentee before: Kong Qingzhong Patentee before: Shandong Lanjin Pharmaceuticals Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: DASEN BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHANDONG ENDUO BIOLOGICAL PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Room 201 Patentee after: DASEN BIOLOGICAL PHARMACEUTICAL CO., LTD. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Room 201 Patentee before: Shandong many biological pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081112 Termination date: 20170203 |